Analysts See $-0.14 EPS for Galectin Therapeutics, Inc. (GALT)

July 14, 2018 - By Andrea Pope

Galectin Therapeutics, Inc. (NASDAQ:GALT) LogoInvestors sentiment increased to 1.86 in Q1 2018. Its up 1.33, from 0.53 in 2017Q4. It increased, as 7 investors sold Galectin Therapeutics, Inc. shares while 7 reduced holdings. 17 funds opened positions while 9 raised stakes. 4.02 million shares or 30.74% more from 3.08 million shares in 2017Q4 were reported.
Morgan Stanley reported 0% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT). Art Advsrs Limited holds 0.01% or 57,775 shares. Riggs Asset Managment Incorporated reported 1,000 shares. Bank Of America De has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Sabby Mgmt Limited Liability Corp has 143,400 shares for 0.08% of their portfolio. Neuberger Berman Ltd holds 0% or 82,494 shares in its portfolio. Optimum Advsr has 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT). Millennium Mngmt Llc holds 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT) or 95,780 shares. Benchmark Cap Advsr stated it has 0.83% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT). Commercial Bank Of Mellon reported 25,809 shares. Blackrock holds 0% or 196,157 shares in its portfolio. Pnc Financial Svcs Group Inc has 51,184 shares. Rathbone Brothers Pcl, a United Kingdom-based fund reported 16,400 shares. Da Davidson And holds 0.07% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 731,300 shares. Tci Wealth Advsrs, a Arizona-based fund reported 300 shares.

Since January 25, 2018, it had 3 insider buys, and 24 sales for $17.06 million activity. The insider 10X Fund – L.P. sold 151,860 shares worth $1.31 million. $1.49M worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) was sold by CZIRR JAMES C. Shares for $602,920 were sold by Shlevin Harold H.. 100,000 shares were sold by TRABER PETER G, worth $751,000. 4,000 shares valued at $14,320 were sold by ZUCCONI THEODORE DANIEL on Monday, April 16. Another trade for 2,000 shares valued at $8,191 was bought by FREEMAN KEVIN D.

Analysts expect Galectin Therapeutics, Inc. (NASDAQ:GALT) to report $-0.14 EPS on August, 13.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.14 EPS. After having $-0.12 EPS previously, Galectin Therapeutics, Inc.’s analysts see 16.67 % EPS growth. The stock decreased 1.06% or $0.07 during the last trading session, reaching $6.55. About 359,917 shares traded. Galectin Therapeutics, Inc. (NASDAQ:GALT) has risen 77.97% since July 14, 2017 and is uptrending. It has outperformed by 65.40% the S&P500.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company has market cap of $247.20 million. The company's lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It currently has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

More notable recent Galectin Therapeutics, Inc. (NASDAQ:GALT) news were published by: which released: “Galectin Therapeutics IPF Patent Solidifies Platform Technology Status” on July 05, 2018, also with their article: “42 Biggest Movers From Yesterday” published on July 06, 2018, published: “2 Clinical-Stage Biotech Stocks That Could Soar Next Week” on June 17, 2018. More interesting news about Galectin Therapeutics, Inc. (NASDAQ:GALT) were released by: and their article: “Mid-Day Market Update: Crude Oil Up Over 3%; Aquinox Pharmaceuticals Shares Plunge” published on June 27, 2018 as well as‘s news article titled: “3 Biotech Stocks That Soared This Week: Are They Buys?” with publication date: June 16, 2018.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.